Albumin uptake through FcRn promotes tumor-associated macrophage maturation and albumin-bound immunotherapy response.
It is shown that tumor-associated macrophages are the dominant nonmalignant albumin-accumulating population in mouse tumors and exhibit the highest per-cell uptake and albumin conjugation prolonged STING-agonist circulation and improved antitumor efficacy versus free agonist in syngeneic tumors.